dr. rugo on the impact of margetuximab based on cd16a fc receptors in her2 breast cancer
Published 4 years ago • 220 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
2:35
dr. rugo on the phase iii sophia trial in her2 breast cancer
-
1:05
dr. rugo on ongoing trials in her2 breast cancer
-
1:26
dr. rugo on rationale for the elaine study in esr1-mutated er /her2- breast cancer
-
1:11
dr. rugo on the significance of the monarch i trial for breast cancer
-
2:43
margetuximab for the treatment of her2-positive breast cancer
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
1:52
dr. rugo on swish trial for hr-positive breast cancer
-
2:11
dr. rugo discusses monarch i in hr her2- breast cancer
-
2:07
dr. rugo on the advances in the treatment of her2-positive breast cancer
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
1:20
dr. hurvitz on the evolution of treatment in metastatic her2 breast cancer
-
4:09
margetuximab for the treatment of her2 breast cancer
-
0:49
dr. o’regan on prognostic value of pcr in her2 breast cancer
-
1:00
dr. blackwell discusses margetuximab for her2 breast cancer
-
1:22
dr. hurvitz on the findings of destiny-breast01 in her2 metastatic breast cancer
-
1:53
dr. hope rugo examines angiogenesis inhibition for advanced breast cancer
-
0:52
dr. o'regan on impact of targeted agents in her2 breast cancer
-
6:41
marianne and bolero-1 trial results in breast cancer
-
1:54
dr. murthy on her2climb trial results in her2 breast cancer